Supporting Biophotonics Companies at all Stages - EPRISE Roadshow Dr. Gerd Illing Oliver Höppner
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
EPRISE Roadshow Supporting Dr. Gerd Illing Oliver Höppner Biophotonics Companies at all Stages © 2018
Who we are Oliver Höppner Gerd Illing ▪ Dipl. Kfm., Business Administration ▪ PhD in Physical Chemistry (TU Berlin) Marketing/ Controlling/ ▪ Biotech/Medtech consultant with Corporate Finance focus on biomedical optics for ▪ > 1997 CFO at NOXXON Pharma AG diagnostic and analytical devices ▪ > 2000 VP Finances at GenProfile AG (biophotonics) ▪ > 2002 supporting life science ▪ >10 years experience as CEO (PSF companies as an interim manager biotech AG, LMTB GmbH) throughout all commercial and ▪ >20 Jahre years in establishing, financial affairs. management and evaluation of ▪ experience along the entire large cross-disciplinary R&D value chain projects ▪ profound network in the areas financing/investing, science and industry. © 2018
1st Perspective: Portfolio Analysis of ICT-Biophotonics Projects/Consortia supported by © 2018
Projects, Programs, Calls, Timelines COBIOPHAD LUCA H2020-ICT-2015-28a INNODERM Some numbers: RAIS 28 projects CARDIS 250 partners INSPECT H2020-ICT-2014-1 SAPHELY 146 M€ total budget DICOMO 101 M€ EU funding M3S 97 project years PHOS-ISTOS CATACURE DIAGNOPTICS CIP-ICT-PSP-2013-7 Current state: Lab2Go ADVANCE 6 completed BabyLux 19 ongoing HEMOSPEC FP7-ICT-2013-10 3 just starting BIOPSYSPEN CAReIOCA BiophotonicsPlus VIAMOS FULLPHASE FP7-ICT-2011-8 BILOBA LiPhos MINERVA FAMOS NANO-VISTA FP7-ICT-2011-7 Phast-ID FP7-ICT-2009-5 SPADnet 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 © 2018 5
Looking for the Medical Need and Coverage (1v2) BABYLUX: DCS-TRS Opthalmology FAMOS: OCT, PA Cerebral Bloodflow/Oxyg. Neonatology CataractCATACURE: Trp-F/Laserbleach Arterial stiffness Onc. ThyroidLUCA: DCS-TRS CARDIS: laser vibrometer Esophageal Cancer FULLPHASE: PA ImagingCVDs Melanoma, AK Minerva: NIR LIPHOS: cell spectrosc.signature DIAGNOPTICS: multimodal Lab2Go cTn I, IVDAcute Myocard Infarct INNODERM, RSOM Staying at the surface: ADVANCE: OCT Skin Malignancies Hemospec: Raman, Fl VIAMOS: OCT Infectious Non-Melanoma BiopsyPen: OCT Diseases Sepsis RAIS: lf-IVD Malaria Keratosis, Psoriasis PHOSISTOS: PDT Optical Biopsy Histo/Pathol/Tissue/Cell CareIOCA: FFOCT M3S: Raman imaging Cameras SPADnet: PET Inspect: Spectrometers CLL for Organs DICOMO: X-ray Head Neck, Larynx Mouth Cancers Onc. Biomarker Pancreas Rheumatoid Arthritis Phast-ID: 2D ph.crystal, lf-IVD FULLPHASE: PA Imaging SAPHELY: miRNA-IVD (Auto)immunology BILOPA: lf-IVD, angiogenesis Allergies Subcellular imaging COBIOPHAD:IgE-IVD CompactDisc Research Tools © 2018 NANO-VISTA: nano-antenna
Looking for the Medical Need and Coverage (2v2) 30 25 • Almost all projects aim at diagnostics, only two at with 20 therapeutic solutions only 15 • All are minimal to non-invasive as desired 10 5 • Label free if invasive is still the great challenge! 0 • Missing? Many! Even some accessible surfaces with great medical relvance are missing • PDT 1x, • Laser surgery/therapy 1x • Neurology 0x • Dentistry 0x • Bronchoscopy 0x • Gynecology: oncology, reproductive 0x • Transfusion medicine (blood products), hematology, renal care…0x © 2018 7
Outcome of 2011 to 2020 ICT Biophotonics Projects Overall Outcome: • … • Shift from components and research tools towards medical systems is clearly visible over the years and along calls. • Very successful at component level, less successful at system level • … Examples: • An earlier project claims medical solutions in opthalmology and oncology, will yield mainly components for OCT. • Another project claims medical solutions for cancer diagnosis, with some chance to deliver. They provided already a number of significantly improved components for NIR applications, some of them world record. • A later project combines working methods into a multimodal system for skin cancer diagnosis with strong commitment to clinical validation, multinational approval. © 2018 8
2nd Perspective… …from in between Companies and Financing © 2018
Our daily business © 2018
Outcome □ Great components □ Not so many great systems / solutions □ Lack of market focus □ No systematic analysis of healthcare systems and players □ Sticking to the wrong ecosystem: „research doctors“ instead of practitioners and patients © 2018
Thank you! Contact: illing@h-lsm.de hoeppner@h-lsm.de c/o van Aubel & Partner Kurfürstendamm 57 10707 Berlin @ Presentation template by SlidesCarnival © 2018
Twenty Years back: Start of… … Infrared and hard X-ray beamlines at BESSY © 2018
Forthcoming ICT Biophotonics Calls □ ICT-03-2018-2019: Advanced optical medical device technologies for medical diagnostics (2019 call): maturing a technology platform and providing access to novel, reliable, robust optical based devices for in-vivo and/or in-vitro medical diagnosis. □ ICT-05-2019: Photonics systems for advanced imaging to support diagnostics driven therapy: Actions should research ground-breaking, reliable (high sensitivity, specificity and accuracy), safe to operate, cost-effective and fast photonics enabled imaging system to support diagnostics during intervention and treatments of major diseases like cancer (excluding skin cancer), infectious, degenerative and cardiovascular diseases. © 2018
You can also read